Immatics (NASDAQ:IMTX) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Immatics (NASDAQ:IMTX) from a sell rating to a hold rating in a research report released on Saturday.

A number of other research analysts also recently weighed in on IMTX. Guggenheim increased their target price on Immatics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Mizuho set a $25.00 price target on shares of Immatics in a research report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immatics in a research note on Thursday, January 22nd. Leerink Partners restated an “outperform” rating and set a $17.00 target price on shares of Immatics in a research report on Thursday, December 4th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of Immatics in a report on Monday, November 24th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immatics has a consensus rating of “Moderate Buy” and an average price target of $19.20.

Immatics Trading Down 2.3%

NASDAQ:IMTX opened at $10.06 on Friday. The company has a market cap of $1.22 billion, a PE ratio of -9.86 and a beta of 1.36. The company has a 50 day simple moving average of $9.89 and a two-hundred day simple moving average of $8.92. Immatics has a 12 month low of $3.30 and a 12 month high of $12.41.

Institutional Investors Weigh In On Immatics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Fox Run Management L.L.C. bought a new stake in Immatics during the 2nd quarter valued at approximately $136,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in Immatics by 28.7% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 31,894 shares of the company’s stock worth $172,000 after purchasing an additional 7,116 shares during the period. Vanguard Personalized Indexing Management LLC purchased a new stake in Immatics during the 2nd quarter valued at approximately $237,000. Aberdeen Group plc raised its position in shares of Immatics by 9.7% during the third quarter. Aberdeen Group plc now owns 789,446 shares of the company’s stock valued at $6,726,000 after buying an additional 69,860 shares during the last quarter. Finally, Burkehill Global Management LP bought a new stake in shares of Immatics during the fourth quarter valued at approximately $1,575,000. 64.41% of the stock is owned by institutional investors.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.